Matches in DBpedia 2016-04 for { ?s ?p "A MEK inhibitor is a chemical or drug that inhibits the mitogen-activated protein kinase kinase enzymes MEK1 and/or MEK2.They can be used to affect the MAPK/ERK pathway which is often overactive in some cancers. (See MAPK/ERK pathway#Clinical significance.)Hence MEK inhibitors have potential for treatment of some cancers, especially BRAF-mutated melanoma, and KRAS/BRAF mutated colorectal cancer.Some MEK inhibitors: Trametinib (GSK1120212), FDA-approved to treat BRAF-mutated melanoma. Also studied in combination with BRAF inhibitor dabrafenib to treat BRAF-mutated melanoma. Selumetinib, had a phase 2 clinical trial for non-small cell lung cancer (NSCLC) which demonstrated an improvement in PFS, and is now in phase III development in KRAS mutation positive NSCLC (SELECT-1,NCT01933932). Other clinical trials underway include uveal melanoma, differentiated thyroid carcinoma, and inoperable plexiforms associated with neurofibromatosis type 1 Cobimetinib or XL518, in a Phase III trial, in combination with vemurafenib (Zelboraf(R)), for treatment of advanced melanoma Binimetinib (MEK162), had phase 1 trial for biliary tract cancer and melanoma and in Sept 2014 reported encouraging results from a phase II clinical trial for NRAS melanoma. PD-325901, for breast cancer, colon cancer, and melanoma CI-1040, PD035901 TAK-733, preclinical for multiple myeloma.↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑"@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- MEK_inhibitor abstract "A MEK inhibitor is a chemical or drug that inhibits the mitogen-activated protein kinase kinase enzymes MEK1 and/or MEK2.They can be used to affect the MAPK/ERK pathway which is often overactive in some cancers. (See MAPK/ERK pathway#Clinical significance.)Hence MEK inhibitors have potential for treatment of some cancers, especially BRAF-mutated melanoma, and KRAS/BRAF mutated colorectal cancer.Some MEK inhibitors: Trametinib (GSK1120212), FDA-approved to treat BRAF-mutated melanoma. Also studied in combination with BRAF inhibitor dabrafenib to treat BRAF-mutated melanoma. Selumetinib, had a phase 2 clinical trial for non-small cell lung cancer (NSCLC) which demonstrated an improvement in PFS, and is now in phase III development in KRAS mutation positive NSCLC (SELECT-1,NCT01933932). Other clinical trials underway include uveal melanoma, differentiated thyroid carcinoma, and inoperable plexiforms associated with neurofibromatosis type 1 Cobimetinib or XL518, in a Phase III trial, in combination with vemurafenib (Zelboraf(R)), for treatment of advanced melanoma Binimetinib (MEK162), had phase 1 trial for biliary tract cancer and melanoma and in Sept 2014 reported encouraging results from a phase II clinical trial for NRAS melanoma. PD-325901, for breast cancer, colon cancer, and melanoma CI-1040, PD035901 TAK-733, preclinical for multiple myeloma.↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑".
- Q17142288 abstract "A MEK inhibitor is a chemical or drug that inhibits the mitogen-activated protein kinase kinase enzymes MEK1 and/or MEK2.They can be used to affect the MAPK/ERK pathway which is often overactive in some cancers. (See MAPK/ERK pathway#Clinical significance.)Hence MEK inhibitors have potential for treatment of some cancers, especially BRAF-mutated melanoma, and KRAS/BRAF mutated colorectal cancer.Some MEK inhibitors: Trametinib (GSK1120212), FDA-approved to treat BRAF-mutated melanoma. Also studied in combination with BRAF inhibitor dabrafenib to treat BRAF-mutated melanoma. Selumetinib, had a phase 2 clinical trial for non-small cell lung cancer (NSCLC) which demonstrated an improvement in PFS, and is now in phase III development in KRAS mutation positive NSCLC (SELECT-1,NCT01933932). Other clinical trials underway include uveal melanoma, differentiated thyroid carcinoma, and inoperable plexiforms associated with neurofibromatosis type 1 Cobimetinib or XL518, in a Phase III trial, in combination with vemurafenib (Zelboraf(R)), for treatment of advanced melanoma Binimetinib (MEK162), had phase 1 trial for biliary tract cancer and melanoma and in Sept 2014 reported encouraging results from a phase II clinical trial for NRAS melanoma. PD-325901, for breast cancer, colon cancer, and melanoma CI-1040, PD035901 TAK-733, preclinical for multiple myeloma.↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑".